Main Therapeutics.
Longevity therapeutics at consumer scale.
Longevity and performance are now the focus of an entire consumer generation. The demand is here. What the category lacks is the consumer infrastructure and engagement to carry it to the scale of the market arriving behind it. The next decade moves longevity from a clinical niche to a global consumer category. The companies that define it will not look like healthcare companies. They will look like operating systems for human performance.
Three forces are converging. Biology is becoming measurable - wearables have normalized tracking sleep, recovery, glucose, VO2 max. Consumers are choosing performance over repair. Health is becoming identity: signaled, tracked, social. Longevity is leaving the clinic and becoming a consumer behavior.
The category will not stay fragmented. Today it splinters across companies that each own one slice. Telehealth distributes. Diagnostics measure. Wearables observe. Pharmacies fulfill. None own what sits beneath them: the science and the longitudinal biomarker data that compounds with every protocol cycle.
We start at the engagement layer. Circle Life makes longevity social, and the data it generates becomes the moat.
The complete thesis and market map are available in the investor dataroom.